TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04350645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: 1g slow bolus of tranexamic acid over 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: 10mls normal saline 0.9% over 2 minutes
Study: NCT01137097

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sentinel lymph node biopsy
Description: Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
Study: NCT03921476

Intervention type: OTHER
Intervention: Online survey
Description: Online survey completion through Northwestern's REDCap

Intervention type: OTHER
Intervention: Online survey
Description: Online survey completion through Northwestern's REDCap
Study: NCT02870556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cervical epidural analgesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical epidural analgesia
Study: NCT00834847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: 40 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin
Description: 40 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravachol®
Description: 40 mg Tablet
Study: NCT01857180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curriculum
Study: NCT01419535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 50mg tablet by mouth every six hours for nine days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 50mg tablet by mouth every six hours for nine days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
Study: NCT04655326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flore
Description: personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
Study: NCT00478712

Intervention type: OTHER
Intervention: Identification of genetic causes of Hirschsprung Disease
Description: Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
Study: NCT04335084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Prophylaxis treatment for COVID-19

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: Prophylaxis treatment for COVID-19
Study: NCT03767426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Subjects are sleep deprived for an entire night

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Deprivation
Description: Subjects are sleep deprived for an entire night

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daytime nap
Description: After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
Study: NCT00810498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy
Description: Exposure for one hour on the Trilogy ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Exposure to participants current ventilator
Study: NCT03478085

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen guided exercise therapy
Description: Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
Study: NCT02099253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 01
Description: Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 01
Description: Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 02
Description: Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
Study: NCT01962948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganetespib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02422004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion
Description: 25 range of motion exercises of the ankle, 5 times per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range of motion
Description: 25 range of motion exercises of the ankle, 5 times per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed weight-bearing
Description: No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed weight-bearing
Description: No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
Study: NCT04227405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connection to community services through case management
Description: Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
Study: NCT00898482

Intervention type: OTHER
Intervention: This is a non-intervention study for all groups.
Description: This is a non-intervention study.

Intervention type: OTHER
Intervention: This is a non-intervention study for all groups.
Description: This is a non-intervention study.

Intervention type: OTHER
Intervention: This is a non-intervention study for all groups.
Description: This is a non-intervention study.

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Non-intervention study.

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Non-intervention study.

Intervention type: OTHER
Intervention: study of socioeconomic and demographic variables
Description: Non-intervention study.
Study: NCT04227405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOGETHER Workshop
Description: Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment Support Services
Description: Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
Study: NCT04954950

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04191564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low perfusion state
Description: reduce SAP below 100 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normal perfusion state
Description: maintain SAP above 100 mmHg
Study: NCT04516850

Intervention type: GENETIC
Intervention: Expression of receptors and activating proteases
Description: Level of expression of the mRNA of the genes encoding ACE2, TMPRSS2, TMPRSS4 and AR along with reference genes (beta-actin and EPCAM) in nasopharyngeal swabs taken from patients tested for COVID-19
Study: NCT03460626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender Oil
Description: The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an odorless oil without any therapeutic effect
Study: NCT01142947

Intervention type: DRUG
Group type: OTHER
Intervention: beclomethasone dipropionate
Description: 160 mcg twice a day (320 mcg per day total)
Study: NCT04516850

Intervention type: GENETIC
Intervention: Polymorphism of the HSD3B1
Description: Formalin-fixed paraffin embedded tissue blocks will be amplified using polymerase chain reaction (PCR) based experiments followed by direct sequencing (Sanger sequencing)
Study: NCT04554654

Intervention type: DIAGNOSTIC_TEST
Intervention: transvaginal ultrasound,
Description: transvaginal ultrasound performed on day of the start of progesterone supplementation and on the day of frozen embryo transfer; serum progesterone level measurement on day of frozen embryo transfer
Study: NCT00358384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pazopanib vehicle
Description: Pazopanib vehicle will be given to subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone valerate
Description: Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
Study: NCT03562442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Smoking cessation with or without professional / medical support
Study: NCT01802879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat was provided as 5, 10 and 20 mg hard gelatin capsules to be taken orally. Patients started on dose from parent protocol and dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
Study: NCT04626999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Bundle ACL Reconstruction
Description: Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Bundle ACL Reconstruction
Description: Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Bundle ACL Reconstruction
Description: Arthroscopy Single Bundle ACL Reconstruction is a procedure to reconstruct the ACL using one bundle.~The procedure uses Hamstring (Gracillis muscle and Semitendinosus muscle) as a graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Bundle ACL Reconstruction
Description: Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Bundle ACL Reconstruction
Description: Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Bundle ACL Reconstruction
Description: Arthroscopy Double Bundle ACL Reconstruction is a procedure to reconstruct the ACL using Two bundles (Double bundle).~The procedure uses Gracillis tendon as a Posterolateral bundle graft and Semitendinosus tendon as an Anteromedial bundle graft.
Study: NCT03936400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy
Description: Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
Study: NCT02935257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAT-41BBZ CAR T-cells
Description: Infusion with CD19CAT-41BBZ CAR T-cells
Study: NCT02407847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care provided by Nurse Practitioners
Description: Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
Study: NCT01190189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix)
Description: 3-dose schedule intramuscularly vaccination
Study: NCT04797429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Support Intervention via Instant Messaging Service Tool (IMS-Tool)
Description: Peer Support via the IMS-tool increases diabetes self-management, improves self-efficiacy, adherence and glycaemic control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antidiabetic therapy according to the current guidelines
Description: In contrast, the control group has to manage their diabetes mellitus type 2 with standard support and without online exchange.
Study: NCT02927678

Intervention type: OTHER
Intervention: white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging
Study: NCT01380652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: pulmonary rehabilitation with strength and endurance training and additionally vibration training
Study: NCT03823820

Intervention type: OTHER
Intervention: Bioimpedance Analyser
Description: Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.

Intervention type: OTHER
Intervention: Bioimpedance Analyser
Description: Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.

Intervention type: OTHER
Intervention: Bioimpedance Analyser
Description: Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.

Intervention type: OTHER
Intervention: Bioimpedance Analyser
Description: Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
Study: NCT02271217

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 7.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine-ER 10mg
Study: NCT01572714

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support Program
Description: The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Program
Description: The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Plus Fatigue Management Education Program
Description: The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
Study: NCT03923270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill
Description: Participants in arm C will be self-administer 300 mg of Olaparib orally.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic Radiotherapy
Description: Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants in arm D will be administered 300 mg of Tremelimumab intravenously in 1 single dose
Study: NCT03900793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for \> 4 hours prior to dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
Study: NCT03426579

Intervention type: DEVICE
Intervention: NeuroSENSE ®in children
Description: Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.